PMID- 10225755
OWN - NLM
STAT- MEDLINE
DCOM- 19990513
LR  - 20191103
IS  - 1091-6660 (Print)
IS  - 1091-6660 (Linking)
VI  - 1
IP  - 2
DP  - 1997 May
TI  - Extracorporeal photochemotherapy: a treatment for organ graft rejection.
PG  - 121-5
AB  - Extracorporeal photochemotherapy (ECPC) has been investigated experimentally and 
      in clinical conditions in transplant rejection treatment and prevention. Repeated 
      injections of photochemically modified syngeneic alloreactive T cells prior to 
      transplant significantly delay rejection in a mouse skin graft model as well as 
      in a heterotopic heart transplant model in rats. In the latter, we found this 
      effect to be dependent on 3 main parameters, i.e., treatment intensity (number of 
      injections), schedule (injections before and after transplant), and associated 
      immunosuppression (because there is no detectable effect in animals without 
      immunosuppression). In human beings, ECPC was first used for the treatment of 
      acute rejection episode after heart transplantation. At least 2 studies provided 
      evidence that ECPC is as effective as high dose corticosteroids in controlling 
      moderate acute rejections, and several case reports showed that ECPC could be 
      effective in recurrent and/or steroid resistant rejections. ECPC has also been 
      investigated in an open trial to prevent rejection episodes after heart 
      transplantation in patients at high risk of acute rejection because of human 
      leukocyte antigen (HLA) immunization and/or a second or third transplant and 
      found to be successful. In heart transplant recipients at standard risk of 
      rejection episodes, a small scale randomized trial showed a reduction in both 
      rejection episodes and infections in the ECPC treated vs. the standard group. 
      Beyond these studies and other isolated case reports, several large scale 
      randomized trials in heart, lung, and even kidney transplantations (some of them 
      already ongoing), will enable us to define the role of ECPC in the management of 
      transplant recipients.
FAU - Heshmati, F
AU  - Heshmati F
FAU - Tavakoli, R
AU  - Tavakoli R
FAU - Michel, A
AU  - Michel A
FAU - Achkar, A
AU  - Achkar A
FAU - Guillemain, R
AU  - Guillemain R
FAU - Couetil, J P
AU  - Couetil JP
FAU - Andreu, G
AU  - Andreu G
LA  - eng
PT  - Editorial
PT  - Review
PL  - United States
TA  - Ther Apher
JT  - Therapeutic apheresis : official journal of the International Society for 
      Apheresis and the Japanese Society for Apheresis
JID - 9706703
SB  - IM
MH  - Animals
MH  - *Graft Rejection
MH  - *Heart Transplantation/immunology
MH  - Humans
MH  - *Lung Transplantation/immunology
MH  - *Photochemotherapy
MH  - Treatment Outcome
RF  - 25
EDAT- 1997/05/01 00:00
MHDA- 1999/05/04 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1999/05/04 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - 10.1111/j.1744-9987.1997.tb00025.x [doi]
PST - ppublish
SO  - Ther Apher. 1997 May;1(2):121-5. doi: 10.1111/j.1744-9987.1997.tb00025.x.